Prudent use of beta2-agonists in the treatment of asthma.
The primary disorder in asthma is airway inflammation, which must be managed with anti-inflammatory agents. A review of recent literature highlights conflicting perspectives of the comparative efficacy and safety of short- and long-acting beta2-agonists and their very different roles in asthma therapy.
Giangrasso
T
T
D000318:Adrenergic beta-Agonists / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy*; D003692:Delayed-Action Preparations; D016527:Drug Costs; D004361:Drug Tolerance; D006801:Humans; D012449:Safety
D000318:Adrenergic beta-Agonists; D003692:Delayed-Action Preparations